Skip to content

Draft, not yet released. In stewardship review. Not indexed until the first approved release.

Methodology

How the edition was made: methods, the model card, the evidence cut and its age, the acceptance record and the glossary.

15 min read0 figures13 tables21 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

अनुक्रमणिका
  1. ·Edition home
  2. ·Executive summary
  3. 1Genomics is data infrastructure and a therapeutic frontier
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
  7. 5Individualised editing outpaces delivery systems
  8. 6Readings from the other desks
  9. 7The 2027 agenda
  10. 8Systems in depth
  11. AMethodology
    1. A.1 Methods
    2. A.2 Model card, Genomics System Model v0
    3. A.3 The baseline evidence cut
    4. A.4 Evidence age and coverage
    5. A.5 Evidence cards, two anchor sources
    6. A.6 Publication acceptance record
    7. A.7 Status words
    8. A.8 How the edition is made, released and corrected
    9. A.9 Glossary and abbreviations
    10. A.10 Technical annex
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

A.1पद्धती

The global baseline uses published values and four simple derivations. Each is shown in full so that any reader can reproduce it.

Table A.1Methods
No.DerivationCalculationनिकाल
(1)Share of evaluable sickle cell patients free of crises29 ÷ 3097%
(2)Share of evaluable thalassaemia patients transfusion independent32 ÷ 3591%
(3)Year-on-year growth in Casgevy revenue, first quarter42.9 ÷ 14.2about 3.0 times
(4)Evaluable share of treated sickle cell patients30 ÷ 4468%
Table A.2Coupling strength scale (matrix and model card)
StrengthDefinition
STRONGa disruption in the source system has historically changed the target system’s service or output within one season, in more than one region
MODERATEan effect is documented but buffered or slower
WEAKan effect is plausible but not documented at global scale
Table A.3Status grammar
लेबलRule
नोंदवलेलेvalue as issued by its source, with year
Inferredreasoned from cited evidence; never a measurement
अंदाजितNexus analytical value with stated method
परिदृश्यconditional on stated assumptions
Expert inputstructured editorial judgement awaiting evidence

A.2Model card, Genomics System Model v0

Model ID
MDL-XT05-GENOMICS · v0.1
Purpose
represent genomics and gene editing as infrastructure coupled to health, compute and energy, trade and supply, finance, workforce and data protection
Family
graph-based system of systems
Inputs
the cited sources of this edition; no proprietary data
पद्धत
expert-specified coupling strengths (STRONG · MODERATE · WEAK) from assessments and analogue events
प्रमाणीकरण
none yet, first validation against federation evidence in 2027
अनिश्चितता
qualitative; strengths are hypotheses, not measurements
Domain of validity
global scale; not for asset-, site- or country-level use
Reproducibility
strength table and sources published in this edition
20couplings

typed in v0

0strong

documented within one season

3moderate

documented, buffered

17weak

plausible, undocumented

A.3The baseline evidence cut

Every Nexus edition is published from a frozen evidence cut. The global baseline cut is documentary: it pins the exact edition of every source cited. Federation cuts begin with the first national Foundry cuts in 2027.

Cut ID
DC-XTECH-GENOMICS-GLOBAL-2026-B0
प्रकार
baseline documentary cut
Resolution policy
pinned · as of 30 September 2026
Sources pinned
44 cited sources, each at the edition and access date in the references
Model runs
none at baseline, analytical values are stated with their method
Digest
computed at freeze and recorded in the publication record
Supersedes
nothing, first cut of the series
Superseded by
the 2027 genomics annual cut

वंशावळ

  1. 01

    source edition

  2. 02

    pinned citation

  3. 03

    finding

  4. 04

    page

  5. 05

    publication record

Table A.4From the baseline cut to the federation cut
ElementBaseline 20262027 global annual
स्रोतcited global publications, pinned by editionnational, regional and sector cuts through one graph
Analysisstated methods and editorial estimatestyped analysis specifications
ModelsGenomics System Model v0 specificationmodel runs with receipts
Findingstwelve baseline findingsfindings re-bound to federation evidence
पुनरावलोकनfive passes scheduledfive passes on the exact digest

A.4Evidence age and coverage

A 2026 global edition rests on evidence observed in many different years. This page shows each time base, so that no single year label hides older evidence.

Table A.5Evidence age and coverage
Indicatorनिरीक्षितReleasedCadenceNext release
Phase 3 sickle cell and thalassaemia reports2024NEJM 2024one-offlonger follow-up
FDA approval2023Dec 2023one-offpaediatric label
Patient-specific base editing report2025NEJM 2025one-offfollow-up
Reference genome and pangenome2022 to 2023Science 2022 · Nature 2023periodicpangenome release 2
Biobank genome releases2024 to 2025Nature 2024 · Nature 2025periodicnext releases
Compute footprint studies2021 to 2022Adv Sci 2021 · MBE 2022one-offnew studies
Vertex company report2026page read 2026-11-03quarterlynext quarterly report
Illumina trade events2025Feb to Nov 2025per eventcurrent status
Table A.6Coverage by system at baseline
प्रणालीव्याप्तीThinnest dimension
TherapiesPARTIALtreatment counts and prices
Data resourcesGOODancestry balance on a common basis
प्रशासनPARTIALnational rule texts
वित्तTHINpayer and price data
ऊर्जाTHINsequencing and cold-chain energy
SupplyTHINconsumables and reagents
SkillsTHINworkforce beyond counselling
Agriculture and environmentTHINedited crop and animal data
Table A.7Designed empty states: what is not bound, what would fill it and why
क्षेत्रSource that would fill itBlocker
Energy and cooling use of sequencing laboratories and cell-therapy cold chainslaboratories, manufacturers, peer-reviewed footprint studiesnot retrieved; only compute footprints were read2122
NHGRI cost per genome series valuesNHGRI sequencing cost data table13the page shows graphs and a linked Excel table; the values were not read
Independent cost per genome at scaleservice providers, national laboratories, published cost studiesonly vendor list prices were read, and the Ultima page shows both USD 60 and USD 801540
Patients treated with editing therapies, by countrycompany reports, treatment centre registries, regulatorsthe full-year 2025 report gives 64 patients infused worldwide, not by country35; the first quarter 2026 report gave no counts6
Prices paid for editing therapiespayers, health technology assessment bodies, company reportsnot retrieved
Number of people with a sequenced genome worldwidenational programmes, vendors, published talliesno consolidated series found
Ancestry balance of genome datasets on a common basiscohort papers and diversity monitorstwo cohorts and two commentaries read16171819
Sequencer fleet and consumable supply by countrytrade statistics, vendor filingsnot retrieved; only trade events were read31
Text of Regulation (EU) 2026/1388 from the Official JournalOfficial Journal of the European Union36text read; adopted 17 June 2026, published 26 June 2026, applies from 17 July 202836
FDA draft guidance on the plausible mechanism pathwayFDA guidance page37the Federal Register notice of availability was read; the draft guidance text was not read537
Date and terms on which the FDA lifted the 2025 clinical holdscompany and FDA notices39company filings only: holds lifted 27 January 2026 and 2 March 2026; no FDA notice read39
National rules on genetic data, somatic editing and heritable editingstatutes and regulatorsnot retrieved; only the Oviedo text was read41
Genomics workforce beyond genetic counsellorsnational statistics, surveysnot retrieved; only counsellor figures were read33
Capability rungs beyond approvals and planningagencies, clinics, laboratoriesnot reviewed

A.5Evidence cards, two anchor sources

Published in the New England Journal of Medicine in 2024 by Frangoul and colleagues. Phase 3 single-group study. Role: binds HLT-001. Coverage: patients 12 to 35 years of age.

EVD-XT05-001

Exagamglogene autotemcel for severe sickle cell disease2

Published in Science in 2022 by the Telomere-to-Telomere Consortium. One-off assembly. Role: binds DAT-006. Coverage: one human cell line genome.

EVD-XT05-002

The complete sequence of a human genome11

Table A.8Quality dimensions at baseline
DimensionEVD-XT05-001EVD-XT05-002
Completenessone disease; 30 evaluable patientsone genome; all chromosomes except Y gapless
Timelinessinterim analysis at median 19.3 monthssingle release in 2022
Revisionfollow-up reports expectedpangenome release builds on it
Method transparencymethods and end points publishedassembly methods published
External validationpeer reviewpeer review

Evidence cards to follow in 2027

  • Frangoul2: follow-up beyond the median 19.3 months
  • Vertex6: counts of patients treated
  • FDA37: draft guidance text
  • Official Journal36: regulation text

A.6Publication acceptance record

Editorial self-check at evidence close. Every applicable item carries a disposition; the remaining items are review, approval and deposit.

Table A.9Publication acceptance record
गटक्षेत्रItemsPassN/APending
D1Identity and scope8800
D2Source and data12912
D3Analysis and models12381
D4Findings and claims9801
D5Figures, tables, maps10622
D6Editorial and citations10802
D7Review and approval130013
D8Artefact and design12705
D9Registry and release9009

Publication gate

Conditions met
14 of 23 at evidence close
Blocking problems
none recorded
Open conditions
reviews, approval of the exact digest, deposit, registry pointer

Not applicable at baseline

Model runs
first runs in Q1 2027
नकाशे
plates in Q2 2027
Waivers
none

A.7Status words

Table A.10The status every value carries
स्थितीयाचा अर्थ काय
निरीक्षितMeasured directly and published by the source.
नोंदवलेलेPublished statistics of an official or institutional source.
DeclaredStated by the body concerned; not independently measured.
अंदाजितA Nexus estimate from cited evidence, with its method in Annex A.
प्रारूपितProduced by a stated model from cited inputs.
InferredReasoned from cited evidence; not measured.
ForecastA projection by the cited source.
SimulatedA simulation result under stated assumptions.
परिदृश्यA conditional statement under stated assumptions; never a prediction.
Expert inputExpert judgement, recorded with its basis.
CandidateProposed for a later edition; not yet evidence.
Evidence-quality levels (EQL 1 to 5) grade the source behind a value; they are not a score of the subject.

A.8How the edition is made, released and corrected

Every edition is built from a sealed evidence cut, reviewed under three keys, signed and deposited before any site shows it as published; corrections go to Nexus Standards as change proposals and feed the next cut.

पायरीWhat happensस्रोत
01 Evidence arrives from the pillarsFoundry seals observations and indicator series, Universe hands over after-action and scenario findings, and contributions are screened at every gateway, including this site’s.
02 The cut is sealedOn the cut date the evidence is pinned under one identifier, so anyone can rebuild the edition from exactly what it was built on.
03 The edition is assembledThe edition is drafted from its template and content pack. Agents may draft; they never publish and never decide.
04 The keys turnAt the publisher of record the truth key comes first: every value is checked against its source or stated method before the meaning and capital keys turn. No edition moves on until every key has been turned by a named steward.
05 The gate opensA named approver releases one exact digest of the edition; any change after this point is a new version, never a silent edit.
06 Signed and depositedThe PDF, the web edition and the data bundle are signed together with a manifest and an RO-Crate description, and deposited on Zenodo with a concept and a version DOI.
07 Published on its desk’s siteOnly then does the edition show as published on its desk’s Reports site, and the Collection lists it as a part.
08 Corrections go to StandardsMethod and correction findings go to Nexus Standards as change proposals; citations, corrections and new contributions feed the next evidence cut.

A teaching model of the process, not a forecast and not a record of any run; dates and counts on this page come from the programme record. Sources: Reports governance at GCRI Canada (2026); Zenodo, repository of record for Reports deposits (2026).

Lifecycle, one state at a time: Draft, Computed, Evidence bound, Reviewed, Approved for release, Published, Corrected, Superseded. This edition is a draft.

A.9Glossary and abbreviations

Table A.11Series terms
TermMeaning
Baseline Editionthe inaugural annual edition that fixes the reference state for the series
WEFH+Bwater, energy, food, health and biodiversity, the national nexus core
जोडणीa typed dependency through which one system transmits to another
Protection gapthe share of losses not covered by insurance
Capability ladderLISTED → EXISTS → ADEQUATE → TESTED → DEMONSTRATED
EQLevidence-quality level, 1–5
Evidence cuta frozen resolution of exact sources and versions
NNC · NLC · NWGNational Nexus Consortium · National Leadership Council · National Working Groups
Table A.12Abbreviations used in this edition
AbbreviationExpansion
bpbase pairs
CRISPRclustered regularly interspaced short palindromic repeats
exa-celexagamglogene autotemcel
FDAUS Food and Drug Administration
GWASgenome-wide association study
LNPlipid nanoparticle
NDAANational Defense Authorization Act
NEJMNew England Journal of Medicine
OMBUS Office of Management and Budget
T2TTelomere-to-Telomere
TDTtransfusion-dependent beta-thalassaemia
WHOजागतिक आरोग्य संघटना

A.10Technical annex

Table A.13Technical annex
ItemAnnexअनुक्रमणिकास्थिती
A.1Indicator definitionsthe global indicator set, with units and sourcesIN THIS EDITION
A.2Coupling strengthsthe twenty-cell matrix and its rationaleIN THIS EDITION
A.3Scenario specificationSCN-XT05-DLV-01 assumptions and signpostsIN THIS EDITION
A.4Capability placementsrung evidence for fifteen functionsIN THIS EDITION
A.5Model diagnosticsfirst runs and validation2027
A.6Sensitivity analysesinfluence of coupling strengths2027
A.7Cluster notescards for the major sequencing and cell-therapy clusters2027
A.8Review statementspass-by-pass review recordAT RELEASE

A.1 · indicator definition: transfusion independence

Construct
a weighted average haemoglobin level of 9 g per decilitre or higher without red-cell transfusion for at least 12 consecutive months
Unit
patients meeting the definition among evaluable patients
पद्धत
prespecified interim analysis of an open-label single-group study
स्रोत
New England Journal of Medicine 20243
अनिश्चितता
95% confidence interval 77 to 98 for the 91% result
Known limits
interim analysis; short follow-up; no comparison arm

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
  2. 22Lannelongue, L., Grealey, J. and Inouye, M., Green Algorithms: Quantifying the Carbon Footprint of Computation, Advanced Science 2021 (abstract read through the Europe PMC record). Wiley, Weinheim. Observation year 2021. Accessed 2026-11-03.back
  3. 13National Human Genome Research Institute (ed.), The Cost of Sequencing a Human Genome (fact sheet page; method notes read; the cost values sit in graphs and a linked table that were not read; page updated 16 May 2023). NHGRI, Bethesda. Observation year 2023. Accessed 2026-11-03.back
  4. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  5. 40Ultima Genomics (ed.), Ultima Genomics increases output by over 50% and lowers sequencing costs by a further 20% with the introduction of UG 100 Solaris (press release, 24 February 2025, read through a wire copy; USD 0.24 per million reads, enabling the USD 80 genome; vendor evidence, weak). Ultima Genomics, Fremont. Observation year 2025. Accessed 2026-11-05.back
  6. 35Vertex Pharmaceuticals (ed.), Vertex Reports Fourth Quarter and Full Year 2025 Financial Results, Form 8-K exhibit 99.1, 12 February 2026 (company filing read; Casgevy revenue USD 115.8 million in 2025 and USD 10.0 million in 2024; 64 patients infused in 2025; company statement, weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-05.back
  7. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back
  8. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  9. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  10. 18Fatumo, S. et al., A roadmap to increase diversity in genomic studies, Nature Medicine 2022 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2022. Accessed 2026-11-03.back
  11. 19Sirugo, G., Williams, S.M. and Tishkoff, S.A., The Missing Diversity in Human Genetic Studies, Cell 2019 (abstract read through the Europe PMC record). Cell Press, Cambridge. Observation year 2019. Accessed 2026-11-03.back
  12. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  13. 36European Parliament and Council of the European Union (eds.), Regulation (EU) 2026/1388 of 17 June 2026 on plants obtained by certain new genomic techniques and their products, and amending Regulation (EU) 2017/625, Official Journal L series, 26 June 2026 (text read; enters into force on the twentieth day after publication; applies from 17 July 2028, with Articles 29 to 31 from 16 July 2026). Publications Office of the European Union, Luxembourg. Observation year 2026. Accessed 2026-11-05.back
  14. 37US Food and Drug Administration (ed.), Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability, Federal Register 91 (37), notice 2026-03713, docket FDA-2026-D-1256, 25 February 2026 (notice read; the draft covers genome editing and RNA-based therapies; comments due 27 April 2026; the guidance text itself was not read). FDA, Silver Spring. Observation year 2026. Accessed 2026-11-05.back
  15. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  16. 39Intellia Therapeutics, Inc. (ed.), Form 8-K of 27 January 2026 and Form 8-K exhibit 99.2 of 2 March 2026 (company filings read; the FDA imposed clinical holds on the MAGNITUDE and MAGNITUDE-2 trials on 29 October 2025 and removed them on 27 January 2026 for MAGNITUDE-2 and on 2 March 2026 for MAGNITUDE, with enhanced liver monitoring; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-05.back
  17. 41Council of Europe (ed.), Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine (Oviedo Convention), Oviedo, 4 April 1997 (text read in the official Spanish publication, Boletin Oficial del Estado BOE-A-1999-20638, 20 October 1999; in force since 1 December 1999; article 13 allows an intervention to modify the human genome only if it does not aim to modify the genome of descendants). Council of Europe, Strasbourg. Observation year 1997. Accessed 2026-11-05.back
  18. 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03.back
  19. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  20. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  21. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back

Downloads

Draft, not yet releasedReview copies of a draft in stewardship review. The released edition carries its DOI and replaces them.

  • Print

    • PDF, A4

      The designed print edition, A4: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF113 pages1.0 MBTagged, with bookmarks

      SHA-256 7276b0b0c2919661f94a296cdb60a579d1cb5466d3fab3011f46a9d5e81e42d6

    • PDF, US Letter

      The designed print edition, US Letter: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF123 pages1.0 MBTagged, with bookmarks

      SHA-256 da38a3579fdd5a3ac5c84f44a22853584be7e987208657578ede146f7b88fd58

  • Web edition

  • Data bundle

    • Indicators, CSV

      16 indicators with unit, year, status and source

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-indicators.csv1 KB

      SHA-256 f1c3fc5ae9f6823c263bb4a464c29a9516551ab806ef2a07fc3e737d1cd85a8d

    • Indicators, JSON

      The same indicators with the edition’s identity and licence

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-indicators.json2 KB

      SHA-256 c54a918f9a805a488a8931ec6c1a235eb273361704df0909aae23d83048aa489

    • Findings, CSV

      12 findings with status, evidence-quality level and references

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-findings.csv3 KB

      SHA-256 0cb51833261dd188ca2af8a452aa38bbf651743f01a98776ff39430d07bcb97f

  • Citation files

    • Citation, BibTeX

      For LaTeX and reference managers

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.bib1 KB

      SHA-256 a09328c6428b83ba58eba3284cc50b50417b9fccd1c4d685a53746ed430fac83

    • Citation, RIS

      For Zotero, EndNote and Mendeley

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.ris1 KB

      SHA-256 95ff0d92b09d48fa348d982302647ab3ab0709cf5aaccccde30e735cade45a16

    • Citation, CITATION.cff

      Citation File Format 1.2.0, for GitHub, Zenodo and software catalogues

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.cff1 KB

      SHA-256 16aeb56c4b5eb0bfe8917c7848aec9209776f6cf7708280877069c0cfe0ef1f2

Check a file with its SHA-256: shasum -a 256 <file> (macOS, Linux) or Get-FileHash <file> (Windows). Text, tables and figures by Nexus: CC BY 4.0; each source keeps its own licence.

Cite this annex

Valadbaygi, S. (Ed.). (2026). Annex A: Methodology. In Exponential Technology Report 2026: Genomics and Gene Editing (Baseline Edition 2026, Report No. NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

अहवालयोगदान द्या

Send evidence or a correction on Genomics and Gene Editing.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

GCRI Systems Evidence deskExponential Technology
Contribution form · reports.contribution.gcri

वैयक्तिक डेटा, संवेदनशील पायाभूत सुविधांचा तपशील किंवा सामायिक करण्याचा तुम्हाला अधिकार नसलेले काहीही कधीही पाठवू नका. योगदानाचे वापरापूर्वी पुनरावलोकन केले जाते; ते पाठवल्याने कोणतेही लेखकत्व किंवा संपादकीय अधिकार मिळत नाहीत, आणि प्रायोजकत्वाने कधीही निष्कर्ष विकत घेता येत नाही.

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.